Evaluating the efficacy of stem cells in treating severe dry eye disease  

作　　者：Lanxing Fu Lucia Pelosini Nick Kopsachilis Roberta Foti Fabiana D’Esposito Mutali Musa Alberto D’Amico Daniele Tognetto Caterina Gagliano Marco Zeppieri 

机构地区：[1]Department of Ophthalmology,East Kent Hospitals University NHS Foundation Trust,Canterbury CT13NG,United Kingdom [2]Department of Ophthalmology,King’s College Hospital NHS Foundation Trust,London SE59RS,United Kingdom [3]Division of Rheumatology,A.O.U.“Policlinico-San Marco,”Catania 95123,Italy [4]Imperial College Ophthalmic Research Group Unit,Imperial College,London NW15QH,United Kingdom [5]Department of Neurosciences,Reproductive Sciences and Dentistry,University of Naples Federico II,Via Pansini 5,80131 Napoli,Italy [6]Department of Optometry,University of Benin,Benin 300283,Nigeria [7]Department of Ophthalmology,Centre for Sight Africa,Nkpor,Onitsha 434112,Nigeria [8]Academic Neurosurgery,Department of Neurosciences,University of Padova,Padova 35128,Italy [9]Department of Medicine,Surgery and Health Sciences,University of Trieste,Trieste 34129,Italy [10]Department of Medicine and Surgery,University of Enna“Kore,”Catania 94100,Italy [11]Caterina Gagliano,Mediterranean Foundation"G.B.Morgagni",95125 Catania,Italy [12]Marco Zeppieri,Department of Ophthalmology,University Hospital of Udine,Udine 33100,Italy

出　　处：《World Journal of Stem Cells》2025年第4期36-47,共12页世界干细胞杂志(英文)

摘　　要：Dry eye disease(DED)is a multifactorial disorder that disturbs ocular surface equilibrium,considerably diminishing quality of life.Present therapies only offer symptomatic alleviation.Stem cell treatment,especially mesenchymal stem cells(MSCs),has surfaced as a viable approach for tissue regeneration and immunological regulation in DED.Preclinical and early clinical investigations indicate that MSCs can improve lacrimal gland functionality,diminish inflammation,and facilitate corneal regeneration.Nonetheless,obstacles persist in enhancing MSC viability,determining the optimal MSC source,and guaranteeing sustained therapeutic effectiveness.Additional extensive randomized clinical trials are required to confirm the efficacy of MSC-based therapies for severe DED.

关 键 词：Dry eye disease Stem cell therapy Mesenchymal stem cells Corneal regeneration EXOSOME CORNEA Clinical trials 

分 类 号：R77[医药卫生—眼科]